Core Viewpoint - Jincheng Pharmaceutical has decided to terminate its intended cooperation project with Giskit Pharma B.V. due to insufficient progress in negotiations and lack of consensus on key issues [1] Summary by Relevant Sections Cooperation Agreement - In August 2024, Jincheng Pharmaceutical and Giskit began negotiations for exclusive commercialization rights in China for Giskit's drug ExEm Foam, which evaluates tubal patency in women with infertility [1] - In September 2024, both parties agreed to extend exclusive negotiations until November 15, 2024, to reach a final agreement [1] - On November 18, 2024, Jincheng disclosed that negotiations on key terms for exclusive distribution were still ongoing after the expiration of the exclusivity period [1] Decision to Terminate - Jincheng Pharmaceutical stated that the cooperation framework agreement was only a preliminary arrangement, and no formal cooperation agreement was signed [1] - The negotiations did not progress as expected, and no substantial advancements were made regarding the cooperation project [1] - After careful consideration of its development strategy and operational circumstances, the company decided to terminate the intended cooperation project [1]

Core Viewpoint - The company has decided to terminate the intention to cooperate with Giskit Pharma B.V. regarding the commercialization rights of ExEm Foam in China due to lack of substantial progress in negotiations [1] Group 1: Cooperation Agreement - The company announced a cooperation framework agreement with Giskit Pharma B.V. for exclusive commercialization rights of ExEm Foam in China [1] - The cooperation framework agreement is an intention-based arrangement, and no formal cooperation agreement has been signed [1] - Negotiations for the cooperation have not progressed as expected, and key issues remain unresolved [1] Group 2: Strategic Decision - The company has conducted a careful review based on its development strategy and operational circumstances [1] - As a result of the review, the company has decided to terminate the intention to cooperate on the project [1]

Core Points - Jin Cheng Pharmaceutical (300233) announced on November 27 that it has been negotiating exclusive commercialization rights for ExEm Foam, a drug owned by Dutch company Giskit, which is used for evaluating tubal patency in women with infertility in China [1] - Both parties have agreed to continue exclusive negotiations to reach a cooperation agreement and have extended the negotiation period until November 15, 2024 [1] - Despite the intention to cooperate, the negotiation progress has not met expectations, and no substantial agreement has been reached on key issues, leading the company to decide to terminate the intended cooperation project [1]